Inside Astellas CEO's 5‑year plan to counter Xtandi's patent cliff

Astellas Pharma CEO Naoki Okamura has outlined a 5‑year strategic plan to counter the impending patent cliff for the $6 billion prostate cancer drug Xtandi, which supports a large share of the company's revenue and will lose exclusivity in key markets starting in 2027.

The strategy goes beyond simple cost cutting:
it rests on three pillars—about 200 billion yen ($1.3 billion) in cumulative annual savings over FY2026–FY2030, aggressive internal R&D reorganization, and a disciplined investment program totaling roughly 850 billion yen ($5.3 billion) over five years in innovation and external deals.

Astellas is centralizing scattered functions, flattening the organization, and internalizing core R&D capabilities around four focus areas:
immuno‑oncology, targeted protein degradation, genetic regulation, and blindness and regeneration; it also plans to pursue value‑enhancing business development and, if the right opportunity arises, a large‑scale acquisition, but explicitly rejects 'rescue M&A' just to fill the Xtandi revenue gap.

The blueprint hinges on transitioning from Xtandi dependence to a portfolio of five strategic brands—Padcev, Vyloy, Izervay, Veozah and Xospata—whose combined growth is projected to more than offset lost Xtandi sales by around 2030, while the cost savings and pipeline‑led investments aim to deliver record‑high revenue again in the mid‑2030s.